Qube Research & Technologies (QRT)
ATNM icon

Qube Research & Technologies (QRT)’s Actinium Pharmaceuticals ATNM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Sell
18,048
-764
-4% -$909 ﹤0.01% 3282
2025
Q4 		$25.6K Sell
18,812
-6,910
-27% -$10.1K ﹤0.01% 3359
2025
Q3 		$41.2K Sell
25,722
-24,210
-48% -$39.4K ﹤0.01% 3203
2025
Q2 		$69.9K Buy
+49,932
New +$74.7K ﹤0.01% 3096
2024
Q4 		– Sell
-215,690
Closed -$405K – 3443
2024
Q3 		$405K Buy
+215,690
New +$852K ﹤0.01% 2338
2024
Q2 		– Sell
-3,193
Closed -$25K – 3797
2024
Q1 		$25K Buy
+3,193
New +$20.5K ﹤0.01% 3648
2023
Q2 		– Sell
-58,339
Closed -$551K – 2379
2023
Q1 		$551K Buy
58,339
+35,867
+160% +$379K ﹤0.01% 1535
2022
Q4 		$239K Sell
22,472
-683
-3% -$6.93K ﹤0.01% 1735
2022
Q3 		$171K Buy
23,155
+4,118
+22% +$25.6K ﹤0.01% 1815
2022
Q2 		$92K Buy
+19,037
New +$108K ﹤0.01% 1967

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ATNM Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Actinium Pharmaceuticals (ATNM) stake by 4.1% in Q1 2026, selling an estimated $909 and leaving 18,048 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

Qube Research & Technologies (QRT) first reported a position in ATNM in Q2 2022 and has held it in 10 quarters since. The position peaked at $551K in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Qube Research & Technologies (QRT) held 18,048 shares of Actinium Pharmaceuticals worth $18K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 764 Actinium Pharmaceuticals shares in Q1 2026, an estimated $909.
  • Actinium Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3282 holding.
  • Qube Research & Technologies (QRT) first reported a position in Actinium Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
  • Qube Research & Technologies (QRT)'s Actinium Pharmaceuticals position peaked at $551K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.